EGF and colorectal cancer: In HT-29 and WiDr colorectal cancer cell lines, combination of 10 μM HT and monoclonal anti-epidermal growth factor receptor (EGFR) antibody cetuximab reduced cell growth, both in the presence and in the absence of epidermal growth factor (EGF) stimulation, inducing G1/S and G2/M phase cell cycle arrest [276].